Cargando…
Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes
OBJECTIVE: Inflammation is associated with pancreatic β-cell apoptosis and reduced insulin sensitivity. Literature suggests that interleukin (IL)-1β may contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). This study aimed to determine the efficacy, safety, and tolerability of LY218910...
Autores principales: | Sloan-Lancaster, Joanne, Abu-Raddad, Eyas, Polzer, John, Miller, Jeffrey W., Scherer, Joel C., De Gaetano, Andrea, Berg, Jolene K., Landschulz, William H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714510/ https://www.ncbi.nlm.nih.gov/pubmed/23514733 http://dx.doi.org/10.2337/dc12-1835 |
Ejemplares similares
-
LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase
por: Sloan-Lancaster, Joanne, et al.
Publicado: (2017) -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017) -
Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor
por: Raddad, E, et al.
Publicado: (2013) -
Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
por: Peng, Sheng-Bin, et al.
Publicado: (2017) -
Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer
por: Bihorel, S, et al.
Publicado: (2017)